TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity.

TSR-033 (0.01-1000 nmol/L, 48 h) 可以增加原代人类 CD4 T细胞和树突状细胞的 IL2 产生，并增强T细胞效应器功能。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

TSR-033 (i.p.,10 mg/kg, twice weekly, 40 days) 在 A549 HuNOG-EXL NSCLC 小鼠肿瘤模型中，对肿瘤生长有中等程度的抑制作用，单独处理终止时TGI 为 23%，而与 TSR-042 联合处理有累积效应，能更大程度地阻碍肿瘤生长，终止时 TGI 为 45%。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

TSR-033 (i.p.,10 mg/kg, twice weekly, 40 days) 在 A549 HuNOG-EXL NSCLC 小鼠肿瘤模型中，对肿瘤生长有中等程度的抑制作用，单独处理终止时TGI 为 23%，而与 TSR-042 联合处理有累积效应，能更大程度地阻碍肿瘤生长，终止时 TGI 为 45%。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Srimoyee Ghosh, et al. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Mol Cancer Ther. 2019 Mar;18(3):632-641.  [Content Brief]